Home/Startups/Evolvere BioSciences
Evolvere BioSciences

Evolvere BioSciences

Summer 2024

Making Next-Generation Antibiotics that Outpace Bacterial Evolution

AI-powered Drug DiscoveryArtificial IntelligenceBiotechTherapeuticsBiotechnology

About Company

🦠🤖 We use our computational models to make next-generation antibiotics that outcompete bacterial evolution and precisely target pathogenic bacteria, without harming good microbes or human cells. ☠️ Current antibiotics stop working because bacteria evolve resistance to them. This makes drug-resistant bacteria a looming global health crisis - already killing more people than malaria and AIDS and it is getting exponentially worse 📈. 🧬 Our approach leverages co-evolutionary protein-protein interaction datasets combined with AI to forecast bacterial mutations and create ‘future-proof’ antibiotics, addressing antibiotic resistance before it develops. This changes the game for how frequently society will need to make new antibiotics and how long our new antibiotics will be able to treat patients 👩‍⚕️. We are a team of biochemists and evolutionary biologists who met at the University of Oxford.

Active Founders

Adam Winnifrith

Adam Winnifrith

Founder

Evolvere (S24), CEO & Co-Founder, MBioChem Oxford, I work at the intersection of bioengineering, protein AI, and automation. E.S.B

Piotr Jedryszek

Piotr Jedryszek

Founder

S24, Evolvere Biosciences, CTO and Co-founder, background in Bio and CompBio

Weronika Slesak

Weronika Slesak

Founder

CSO at Evolvere (S24). Oxford biologist using evolution as an engineering tool.

Company Facts

LocationOxford, England, United Kingdom
Team Size3
Founded2024
StatusActive